Has David Tran received payments from drug or device companies?

Yes. Drug and device makers reported $128,470 in general payments to David Tran across 76 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Tran did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Tran come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Tran

Medical Oncology · Los Angeles, CANPI 1184747024

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 89.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $44,395 and has fallen 53.2% since, to $20,781 in 2025.

$128,470in general payments, 2019–2025

Across 76 payments — averaging $1690.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novocure Inc.$115K
Novocure GmbH$9K
Monteris Medical Corporation$4K
Telix Pharmaceuticals$133
Abbott$31
AbbVie$17
plus $11 from 1 others

$2,930,676in research payments, 2019–2025

Across 36 payments — averaging $81,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure Inc.$1.3M
Sarepta Therapeutics, Inc.$493K
Novocure Israel Ltd$482K
Novocure GmbH$299K
Monteris Medical Corporation$237K
Merck$108K
plus $19K from 1 others

What the payments were for

Consulting fees$53,43942%
Speaking & faculty fees$27,68522%
Travel & lodging$44,84435%
Food & beverage$2,5022%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novocure Inc.	64	$114,882
Novocure GmbH	3	$9,341
Monteris Medical Corporation	4	$4,055
Telix Pharmaceuticals	1	$133
Abbott	2	$31
AbbVie	1	$17
Novo Nordisk	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,470 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Other medical oncology in Los Angeles

Stephen LiuLos Angeles$750K
Jacek PinskiLos Angeles$672K
Mark AgulnikLos Angeles$303K
Heinz-Josef LenzLos Angeles$185K
Syma IqbalLos Angeles$178K
Anthony El-KhoueiryLos Angeles$156K
David QuinnLos Angeles$134K
Afsaneh BarziLos Angeles$107K
Stephen SherwinSan Francisco$6.9M
Noam DrazinBeverly Hills$1.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →